---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-004122"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-08-13T20:02:40+00:00"
generated_at: "2026-08-13T20:04:14.822679+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Silexion closes $2.5M public offering; converts $750K debt to equity

## Summary
- Offered 2,028,619 shares, 1,817,542 pre-funded warrants, 3,846,161 Series E warrants at $0.65/unit; gross proceeds ~$2.5M.
- Net proceeds ~$2.1M; intended for SIL204 clinical trial and general corporate purposes.
- Converted $750,001 of sponsor note into 1,153,848 ordinary shares at $0.65/share; note balance now $206,462.
- Issued 823,770 shares from pre-funded warrant exercises; adjusted shareholders' equity ~$3.2M as of June 30, 2026.
- H.C. Wainwright sole placement agent; fees 7% cash, 1% management, plus 269,231 placement agent warrants.

## SEC filing metadata
- accession: 0001178913-26-004122
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-08-13T20:02:40+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326004122/0001178913-26-004122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326004122/zk2635949.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-004122
- JSON: https://secwatch.observer/filing/0001178913-26-004122.json
- Plain text: https://secwatch.observer/filing/0001178913-26-004122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.